Neuroone Medical Technologies Stock Earnings Reports

NeuroOne reported sequential revenue growth in Q1 FY2026 with product revenue of $2.9M (down year-over-year due to prior-year Zimmer stocking). Management projects FY2026 revenue of at least $10.5M (≥17% growth vs FY2025). Clinical adoption of the OneRF brain ablation system accelerated — nearly half of all ablations since launch occurred in Q1 — and the company is establishing a patient registry. The OneRF trigeminal nerve system received FDA 510(k) clearance; a limited commercial launch treated 9 patients across 3 centers with all patients reported pain-free to date, and diligence with a strategic partner is underway. The drug-delivery program was accelerated (devices expected for investigational/animal use in Q3 FY2026, ~6 months earlier than planned) and advisory boards and pharma discussions are in progress. Two lower-back pain programs (percutaneous paddle electrode and basivertebral nerve ablation) are advancing with upcoming animal studies and strategic discussions. Board strengthened with Jason Mills (Penumbra/Boston Scientific background). Financials: product gross margin ~54.2%, total OpEx ~$3.3M, net loss $1.4M ($0.03/share). Cash was $3.6M at 12/31/25; management states the company is funded through FY2026 (potentially longer if milestones are met). No debt outstanding. Management will attend investor conferences and plans continued program updates.